Literature DB >> 2107876

Chemical modification of erythropoietin: an increase in in vitro activity by guanidination.

R Satake1, H Kozutsumi, M Takeuchi, K Asano.   

Abstract

Human recombinant erythropoietin (rHuEPO) was chemically modified with several group-specific reagents in order to study the role of each kind of amino-acid residue in its biological activity. Guanidination of the amino groups of the lysine residues yielded derivatives that showed higher activities in vitro than native rHuEPO, whereas amidination had no effect on the activity. By contrast, modification of the positive charges of the lysine residues to neutral or negative charges, such as in carbamylation, trinitrophenylation, acetylation or succinylation, caused a significant loss of rHuEPO activity. Chemical modification of other amino-acid residues, such as arginine and tyrosine residues or carboxyl groups, also led to loss of activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107876     DOI: 10.1016/0167-4838(90)90020-g

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Effects of amino acids and albumin on erythropoietin carbamoylation.

Authors:  Kyubok Jin
Journal:  Clin Exp Nephrol       Date:  2012-12-11       Impact factor: 2.801

2.  Guanidination of soluble lysine-rich cyanophycin yields a homoarginine-containing polyamide.

Authors:  Maja Frommeyer; Klaus Bergander; Alexander Steinbüchel
Journal:  Appl Environ Microbiol       Date:  2014-02-07       Impact factor: 4.792

Review 3.  The receptor that tames the innate immune response.

Authors:  Michael Brines; Anthony Cerami
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

4.  Recombinant human erythropoietin (rHuEPO): cross-linking with disuccinimidyl esters and identification of the interfacing domains in EPO.

Authors:  M Haniu; L O Narhi; T Arakawa; S Elliott; M F Rohde
Journal:  Protein Sci       Date:  1993-09       Impact factor: 6.725

5.  Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production.

Authors:  S Chattong; J Tanamai; P Kiatsomchai; M Nakatsu; A Sereemaspun; N Pimpha; K Praditpornsilpa; R Rojanathanes; A Sethpakadee; K Tungsanga; S Eiam-Ong; K Manotham
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 6.  Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care.

Authors:  Nimesh S A Patel; Kiran K Nandra; Christoph Thiemermann
Journal:  Crit Care       Date:  2012-07-26       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.